Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Patricia Iranzo"'
Autor:
Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez‐Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo‐Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 779-791 (2023)
Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis are the main therapeutic option for patients with advanced non‐small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients b
Externí odkaz:
https://doaj.org/article/604e6cdc2d234a06b5347b1a01ff2632
Autor:
Susana Cedres, Juan-David Assaf, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, David Marmolejo, Alejandra Rezqallah, Caterina Carbonell, Joan Frigola, Ramon Amat, Anna Pedrola, Rodrigo Dienstmann, Enriqueta Felip
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to histology. The objective of this study is to characterize the impact of chemotherapy a
Externí odkaz:
https://doaj.org/article/dda7bac31e5741c2aadbfeb55a39dc46
Autor:
Joan Frigola, Alejandro Navarro, Caterina Carbonell, Ana Callejo, Patricia Iranzo, Susana Cedrés, Alex Martinez‐Marti, Nuria Pardo, Nadia Saoudi‐Gonzalez, Debora Martinez, Jose Jimenez, Irene Sansano, Francesco M. Mancuso, Paolo Nuciforo, Luis M. Montuenga, Montse Sánchez‐Cespedes, Aleix Prat, Ana Vivancos, Enriqueta Felip, Ramon Amat
Publikováno v:
Molecular Oncology, Vol 15, Iss 4, Pp 887-900 (2021)
Immunotherapy has transformed advanced non‐small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long‐lasting responses in some patients. However, the molecular determinants driving these long‐term responses remain el
Externí odkaz:
https://doaj.org/article/5d71f89668ed4454856fe4896f4856ea
Autor:
Patricia Iranzo, Ana Callejo, Juan David Assaf, Gaspar Molina, Daniel Esteban Lopez, David Garcia-Illescas, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Susana Cedres, Caterina Carbonell, Joan Frigola, Ramon Amat, Enriqueta Felip
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
In recent years, immunotherapy-based regimens have been included into the treatment's algorithm of several cancer types. Programmed death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) interact with their ligands found on the surface of antig
Externí odkaz:
https://doaj.org/article/68096871b81a4586b6908a2820df93e1
Autor:
Enriqueta Felip, Ana Vivancos, Susana Cedres, Alex Martinez-Marti, Alejandro Navarro, Joan Frigola, Caterina Carbonell, Nuria Pardo, Ana Callejo, Mireia Soleda, Jose Jimenez, Javier Hernandez-Losa, Ramon Amat, Patricia Iranzo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Background Immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1/programmed death-ligand 1 axis have transformed the management of advanced non-small cell lung cancer (NSCLC). However, many patients do not benefit from this type o
Externí odkaz:
https://doaj.org/article/0ce84dcbbab841f6820d6a2c75384bf4
Autor:
Oriol Mirallas, Marc Bosch-Schips, Nuria Pardo, Anton Aubanell, Maria Teresa Salcedo-Allende, Ana Callejo, Patricia Iranzo, Josep Tabernero, Enriqueta Felip
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Hepatic rupture is a rare complication of solid tumor malignancies, notably in lung adenocarcinomas, and carries an extremely poor overall prognosis. Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma predict benefit with tyrosi
Externí odkaz:
https://doaj.org/article/5f193692ed6746ee8afd6bce3e272f80
Autor:
Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez‐Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo‐Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip
Publikováno v:
Scientia
Immune checkpoint inhibitors; Liquid biopsy Inhibidores del punto de control inmunitario; Biopsia líquida Inhibidors del punt de control immunitari; Biòpsia líquida Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4156dbba9cbf2c8c3049073dd52fe1ee
https://doi.org/10.1002/1878-0261.13409
https://doi.org/10.1002/1878-0261.13409
Autor:
null Caterina Carbonell, null Joan Frigola, null Nuria Pardo, null Ana Callejo, null Patricia Iranzo, null Augusto Valdivia, null Ilaria Priano, null Susana Cedrés, null Alex Martinez‐Marti, null Alejandro Navarro, null Laura Lenza, null Mireia Soleda, null Javier Gonzalo‐Ruiz, null Ana Vivancos, null Miriam Sansó, null Enric Carcereny, null Teresa Morán, null Ramon Amat, null Enriqueta Felip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53fb5ec0ecd09e6431a3b5b7a48b0577
https://doi.org/10.1002/1878-0261.13409/v2/response1
https://doi.org/10.1002/1878-0261.13409/v2/response1
Autor:
Ignacio Juez, Ana Ruiz-Casado, Carles Pericay, Vicente Alonso, José M Cabrera, Maria Jose Safont, M. Salgado, Pilar Escudero, Ruth Vera, Fernando Rivera, Patricia Iranzo, E. González, Nieves P Martínez, Elena Mata, Carlos F. Lopez, Beatriz González
Publikováno v:
International Journal of Colorectal Disease. 35:739-746
To determine the efficacy and safety data of aflibercept + FOLFIRI in wt RAS mCRC patients after progression to standard chemotherapy + anti-EGFR treatment. Retrospective, observational study in real life conducted in wt RAS mCRC patients treated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ea64652cafc4c6a4d5a46886b4d2443
https://doi.org/10.1007/s00384-020-03509-x
https://doi.org/10.1007/s00384-020-03509-x
Autor:
Joan Frigola, Caterina Carbonell, Patricia Iranzo, Nuria Pardo, Ana Callejo, Susana Cedres, Alex Martinez-Marti, Alejandro Navarro, Mireia Soleda, Jose Jimenez, Javier Hernandez-Losa, Ana Vivancos, Enriqueta Felip, Ramon Amat
Publikováno v:
Scientia
Immunotherapy; Lung neoplasms; Tumor biomarkers Immunoteràpia; Càncer de pulmó; Biomarcadors tumorals Inmunoterapia; Cáncer de pulmón; Biomarcadores tumorales Background Immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1/p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39f834950e7512bed71d08aa0a1cfcd3
https://pubmed.ncbi.nlm.nih.gov/35697380
https://pubmed.ncbi.nlm.nih.gov/35697380